jobs

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Abiomed, Inc.

FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
First Patients in the World Treated with Impella RP Flex with SmartAssist
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed Creates Patient Assistance Program to Address Disparities in Healthcare
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
MedTechVets Appoints Patrice Sutherland, Enterprise Executive Director at Integra LifeScience, as New Board Chairperson
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
U.S. FDA Grants 510(k) Clearance for Impella Low Profile Sheath
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Yale University Study Demonstrates Significant Survival Benefit in High-Risk PCI with Impella Support
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed Second Quarter Fiscal 2023 Earnings and Conference Call Notification
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Multi-Center, Multi-Society Study of Impella-supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77%
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81%
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Unloading with Impella for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
TCT 2022: Impella Enables Complete Revascularization, Improved Quality of Life and Native Heart Recovery
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
ABIOMED Announces First Quarter Record Revenue of $277 Million, up 10% Year Over Year, up 12% in Constant Currency*
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed First Quarter Fiscal 2023 Earnings and Conference Call Notification
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed to Host Investor Call on Heart Failure Opportunity With Impella 5.5 and Impella BTR Heart Pumps
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed Announces Fourth Quarter Record Revenue of $270 Million, up 12% Year Over Year
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed Fourth Quarter Fiscal 2022 Earnings and Conference Call Notification
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
First Patient in Japan Treated with Impella 5.5 with SmartAssist
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed to Host Investor Call on Impella ECP, the World’s Smallest Heart Pump at 9 French
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed to Present at the SVB Leerink 11th Annual Global Healthcare Conference
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed Announces Record Revenue of $261 Million, up 13% Year Over Year
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed Third Quarter Fiscal 2022 Earnings and Conference Call Notification
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Regulators Approve Impella 5.5 With SmartAssist in Japan and Hong Kong; US FDA Grants Impella BTR Conditional IDE Approval for First-in-Human Early Feasibility Study
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Abiomed to Present at Upcoming Investor Conferences
From Abiomed, Inc.
Via Business Wire
Tickers ABMD
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News Instagram Instagram
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

922 Allowance Ave SE
Medicine Hat, AB T1A 3G7

Office hours: 8:30 a.m.-4:30 p.m. Monday to Friday, closed Saturday Sunday and statutory holidays.

[P] 403.527.1101
[F] 403-527-0737

Print Advertising: 403.528.5659
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2024 The Medicine Hat News